Cargando…

Individuals living with lupus: findings from the LUPUS UK Members Survey 2014

Systemic lupus erythematosus (SLE) is a complex and unpredictable disease which varies greatly among patients and has a significant impact on an individual’s daily living and quality of life. A better understanding of the patients’ experiences with the disease is vital to the effective management of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morgan, C, Bland, A R, Maker, C, Dunnage, J, Bruce, I N
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Lupus around the World
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888773/ https://www.ncbi.nlm.nih.gov/pubmed/29310537 http://dx.doi.org/10.1177/0961203317749746

Ejemplares similares

The cost of flares among patients with systemic lupus erythematosus with and without lupus nephritis in the United States
por: Bell, Christopher F, et al.
Publicado: (2022)

Evolving phenotype of systemic lupus erythematosus in Caucasians: low incidence of lupus nephritis, high burden of neuropsychiatric disease and increased rates of late-onset lupus in the ‘Attikon’ cohort
por: Nikolopoulos, D, et al.
Publicado: (2020)

Literature review of lupus nephritis From the Arabian Gulf region
por: Al-Shujairi, Arwa, et al.
Publicado: (2022)

The landscape of systemic lupus erythematosus in Brazil: An expert panel review and recommendations
por: Klumb, Evandro Mendes, et al.
Publicado: (2021)

Multimorbidity among incident Finnish systemic lupus erythematosus patients during 2000–2017
por: Kariniemi, Simo, et al.
Publicado: (2020)

Incidence and prevalence of systemic lupus erythematosus in New Zealand from the national administrative datasets
por: Lao, Chunhuan, et al.
Publicado: (2023)

The majority of Swedish systemic lupus erythematosus patients are still affected by irreversible organ impairment: factors related to damage accrual in two regional cohorts
por: Frodlund, M, et al.
Publicado: (2019)

Differences and similarities of proliferative and non-proliferative forms of biopsy-proven lupus nephritis: Single centre, cross-disciplinary experience
por: Duran, Emine, et al.
Publicado: (2022)

Worse long-term renal outcome of lupus nephritis patients of African descent living in Europe
por: Enfrein, Antoine, et al.
Publicado: (2022)

Escaping the catch 22 of lupus anticoagulant testing
por: Vinholt, Pernille Just, et al.
Publicado: (2020)

Predictors of renal damage in systemic lupus erythematous patients: data from a multiethnic, multinational Latin American lupus cohort (GLADEL)
por: Reátegui-Sokolova, Cristina, et al.
Publicado: (2020)

Medical education: Changes and perspectives
por: Zhang, Qin, et al.
Publicado: (2013)

Real-world Effectiveness of the Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S Vaccines Against SARS-CoV-2 in Solid Organ and Islet Transplant Recipients
por: Callaghan, Chris J., et al.
Publicado: (2022)

Therapeutic implications of the anergic/postactivated status of B cells in systemic lupus erythematosus
por: Dörner, Thomas, et al.
Publicado: (2020)

Systemic lupus erythematosus: state of the art on clinical practice guidelines
por: Tamirou, Farah, et al.
Publicado: (2019)

Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis
por: Morand, Eric, et al.
Publicado: (2023)

Differential regulation of the interferon response in systemic lupus erythematosus distinguishes patients of Asian ancestry
por: Rector, Ian, et al.
Publicado: (2023)

Dissecting signalling pathways associated with intrarenal synthesis of complement components in lupus nephritis
por: Tampe, Desiree, et al.
Publicado: (2022)

Urine and serum S100A8/A9 and S100A12 associate with active lupus nephritis and may predict response to rituximab treatment
por: Davies, Jennifer C, et al.
Publicado: (2020)

Stroke in systemic lupus erythematosus: a meta-analysis of population-based cohort studies
por: Holmqvist, Marie, et al.
Publicado: (2015)

Development and external validation of a prediction model for venous thromboembolism in systemic lupus erythematosus
por: You, Hanxiao, et al.
Publicado: (2023)

Autoantibodies against specific post-translationally modified proteins are present in patients with lupus and associate with major neuropsychiatric manifestations
por: Monahan, Rory C, et al.
Publicado: (2022)

Systemic lupus erythematosus; stroke and myocardial infarction risk: a systematic review and meta-analysis
por: Yazdany, Jinoos, et al.
Publicado: (2020)

White matter hyperintensities associate with cognitive slowing in patients with systemic lupus erythematosus and neuropsychiatric symptoms
por: Monahan, Rory Caitlin, et al.
Publicado: (2021)

Fetal and maternal morbidity in pregnant patients with Lupus: a 10-year US nationwide analysis
por: Mehta, Bella, et al.
Publicado: (2023)

Four trajectories of 24-hour urine protein levels in real-world lupus nephritis cohorts
por: Zhang, Danting, et al.
Publicado: (2023)

Viewpoint on anifrolumab in patients with systemic lupus erythematosus and a high unmet need in clinical practice
por: Tanaka, Yoshiya
Publicado: (2023)

Endothelial dysfunction is associated with activation of the type I interferon system and platelets in patients with systemic lupus erythematosus
por: Tydén, Helena, et al.
Publicado: (2017)

Validation of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in an academic tertiary care centre
por: Schmidtmann, Irene, et al.
Publicado: (2023)

Applying the 2019 EULAR/ACR lupus criteria to patients from an established cohort: a Latin American perspective
por: Pons-Estel, Guillermo J, et al.
Publicado: (2020)

Preclinical to clinical translation of cenerimod, a novel S1P(1) receptor modulator, in systemic lupus erythematosus
por: Strasser, Daniel S, et al.
Publicado: (2020)

Impact of fatigue on health-related quality of life and illness perception in a monocentric cohort of patients with systemic lupus erythematosus
por: Elefante, Elena, et al.
Publicado: (2020)

Fatigue is independently associated with disease activity assessed using the Physician Global Assessment but not the SLEDAI in patients with systemic lupus erythematosus
por: Mertz, Philippe, et al.
Publicado: (2022)

Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I/II trial
por: Wang, Huijing, et al.
Publicado: (2022)

Lipid management in systemic lupus erythematosus according to risk classifiers suggested by the European Society of Cardiology and disease-related risk factors reported by the EULAR recommendations
por: Drosos, George C, et al.
Publicado: (2023)

Role of P-glycoprotein on CD69(+)CD4(+) cells in the pathogenesis of proliferative lupus nephritis and non-responsiveness to immunosuppressive therapy
por: Tsujimura, Shizuyo, et al.
Publicado: (2017)

Performance of the proposed ACR–EULAR classification criteria for systemic lupus erythematosus (SLE) in a cohort of patients with SLE with neuropsychiatric symptoms
por: Gegenava, Maka, et al.
Publicado: (2019)

Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy
por: Baker, Matthew, et al.
Publicado: (2020)

Circulating mitochondrial DNA copy numbers represent a sensitive marker for diagnosis and monitoring of disease activity in systemic lupus erythematosus
por: Giaglis, Stavros, et al.
Publicado: (2021)

Glucocorticoid tapering and associated outcome in patients with newly diagnosed systemic lupus erythematosus: the real-world GULP prospective observational study
por: Floris, Alberto, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qmrob6509pdk12mb7hslbe0lse